Economic aspects of the hygiene management of multiresistant pathogens in in-patient facilities using the example of MRSA;Ökonomische aspekte des hygienemanagements multiresistenter erreger in stationären einrichtungen am beispiel von MRSA

Umweltmedizin in Forschung und Praxis

Volumn 15, Issue 6, 2010, Pages 317-328

  Hübner, Nils Olaf ^a   Tübbicke, Andrea ^a   Hübner, Claudia ^a   Kramer, Axel ^a   Fleßa, Steffen ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Lehrstuhl für Allgemeine Betriebswirtschaftslehre und Gesundheitsmanagement   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 78651400183     PISSN: 14308681     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Voss A, Doebbeling BN (1995): The worldwide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 5(2): 101-106
2. Kresken M, Hafner D (2000): Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft "Resistenz" in der Paul-Ehrlich-GesellschaftfürChemotherapie e.V. aus dem Jahre 1998. Chemotherapie Journal. 9(2): 51-86
3. ShorrAF(2007): Epidemiology and economic impact of meticillinresistant Staphylococcus aureus: review and analysis of the literature. PharmacoEconomics. 25(9): 751
4. Witte W, Kresken M, Braulke C, Cuny C(1997):Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals. Clin Microbiol Infect. 3(4): 414-422
5. Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. Oct 14; 15(41): 19688
6. Grabe C, Buckard R, El-Ansari T, Käflein R. (2010): Flächendeckendes einmonatiges MRSA-Prävalenzscreening in Akut- und Rehakliniken in Siegen-Wittgenstein. Epidemiologisches Bulletin. 18
7. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im Intereuropäischen Raum. Bericht überdie Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-EhrlichGesellschaft für Chemotherapie e.V. aus dem Jahre 2004. PaulEhrlich-Gesellschaft für ChemotherapieeV.2004;htfp./www.p- eg.org/ag-resistenz/main.htm
8. Voss A, Bradley N, Doebbeling (1995): The worldwide prevalence of methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents. 5:101-106
9. Gould I(2006;): Costs of hospital-acquired methicillin-resistant Staphylococcus aureus(MRSA) and its control. International Journal of Antimicrobial Agents. 28(5): 379-384
10. Fleßa S (2007 ): Gesundheitsökonomik: eine Einführung in das wirtschaftliche Denken für Mediziner. Berlin: Springer
11. Korczak D, Schöffmann C (2010): HTA Bericht: Medizinische Wirksamkeit und Kosten-Effektivität von Präventions- und Kontrollmaßnahmen gegen Methicillin-resistenteStaphylokokkusaureus (MRSA)-Infektionen im Krankenhaus. Köln: DIMDI
12. Herr CE, Heckrodt TH, Hofmann FA, Schnettler R, Eikmann TF (2003): Additional costs for preventing the spread of methicillinresistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol. 24(9): 673-678
13. Kanerva M, Blom MJuominen U, Kolho E, Anttila VJ, Vaara M, et al. (2007): Costs of an outbreak of meticillin-resistant Staphylococcus aureus. J Hosp Infect. 66(1): 22-28
14. Björholt I, Haglind E(2004):Cost-savingsachieved by eradication of epidemic methicillin-resistant Staphylococcusaureus (EMRSA)-16 from a large teaching hospital. European Journal of Clinical Microbiology & Infectious Diseases. 23(9): 695
15. Diller R, Sonntag A, Mellmann A, Grevener K, Senninger N, Kipp F, et al. (2008): Evidence for mittelcost reduction based on preadmission MRSA screening in general surgery. International Journal of Hygiene and Environmental Health. 211(1-2): 205-212
16. Zastrow K, Popp W, MRSA als Berufskrankheit. http://www.dgkh.de/ informationen/278: DGKH 2010
17. Henderson D(2003):Managing methicillin-resistant staphylococci: A paradigm for preventing nosocomial transmission of resistant organisms. American Journal of Infection Control. 34(5): S46-s54
18. Safdar N, Maki DG(2004): Quality of care and satisfaction among patients isolated for infection control. Jama. 28; 291(4): 420-1; author reply 1-2
19. Suetens C, Niclaes L, Jans B, Verhaegen J, Schuermans A, Van Eldere J, et al. (2006): Methicillin-resistant Staphylococcus aureus colonization is associated with higher mortality in nursing home residents with impaired cognitive status. J Am Geriatr Soc. 54(12): 1854-1860
20. Safdar N, Bradley EA (2008): The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med. 121 (4): 310-315
21. Nixon M, Jackson B, Varghese P, Jenkins D, Taylor G (2006): Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. J Bone Joint Surg Br. 88(6): 812-817
22. Resch A, Wilke M, Fink C (2008):Thecostofresistance:incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals.The European Journal of Health Economics
23. Reed SD, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, Stryjewski ME, et al. (2005): Costs and Outcomes among Hemodialysisdependent Patients with Methicillin-resistant or Methicillin-Susceptible Staphylococcus Aureus Bacteremia. Journal of Clinical Microbiology. 26(2):175-183
24. Abramson MA, Sexton DJ (1999): Nosocomial Methicillin-resistant and Methicillin-Susceptible Staphylococcus Aureus Primary Bacteremia: AT WHAT COSTS? Direct. 408-411
25. GreinerW, Rasch A, Köhler D, Salzberger B, FätkenheuerG, Leidig M(2007):Clinical outcome and costs of nosocomial and communityacquired Staphylococcusaureus bloodstream infection in haemodialysis patients. Clinical Microbiology and Infection. 13(3): 264
26. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK (2005): Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect. 11 (6): 466-471
27. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH (2006): Morbidity and cost burden of methicillin-resistant Staphylococcus aureusin early onset ventilator-associated pneumonia.Crit Care. 10(3):R97
28. Lehnhof T(2010): Attributierbare ökonomische Konsequenzen einer Kolonisation mit Methicillin-resistenten Staphylococcus aureus (MRSA)
29. Geldner G, Ruoff M, Kiefer P, Georgieff M, Wiedeck H (1999):Kostenanalyse von MRSA-Infektionen auf einer operativen Intensivstation. Anästhesiol Intensivmed Notfallmed Schmerzther. 413
30. Saßmann V, editor (2009): MRSA im DRG-System Status Quo und Perspektiven. Symposium für die Mikrobiologische Diagnostik; Münster
31. Hübner N, Kramer A (2008): Antibiotikaresistenz bei Staphylococcusaureus-Implikationen für ambulantes Operieren. Ambulante Chirurgie. 12(1): 30-33
32. Helfrich J (2008): Multiresistente Erreger aus Sicht der Kostenträger. Auftaktveranstaltung Expertengruppe Multiresistente Erreger im Krankenhaus - Neue Standards für Patientensicherheit; 18.09.2008; Berlin
33. MoewsV(2010): Multiresistente Erreger aus Sicht der Kostenträger. BCV Livescienceforum 2010. Greifswald
34. Leonard FC, Markey BK(2008): Methicillin-resistant Staphylococcus aureus in animals: a review. Vet J. 175(1): 27-36
35. McLean CL, Ness MG (2008): Methicillin-resistantStaphylococcus aureus in a veterinary orthopaedic referral hospital: staff nasal colonisation and incidence of clinical cases. J Small Anim Pract. 49(4): 170-177
36. Sergio DM, Koh TH, Hsu LY, Ogden BE, Goh AL, Chow PK (2007): Investigation of meticillinresistant Staphylococcusaureus in pigs used for research. J Med Microbiol. 56(Pt 8): 1107-1109
37. Wulf MW, Tiemersma E, Kluytmans J, Bogaers D, Leenders AC, Jansen MW, et al. (2008): MRSA carriage in healthcare personnel incontact with farm animals. J Hosp Infect. 70(2): 186-190
38. Karchmer TB, Durbin Li, Simonton BM, Farr BM (2002):Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect. 51(2): 126-132
39. Kola A, Chaberny IF, Mattner F, Reischl U, Vonberg RP, Weist K, et al. (2006): [Control of methicillin-resistant S. aureus by active surveillance. Results of a workshop held by the Deutsche Gesellschaft für Hygiene und Mikrobiologie]. Anaesthesist. 55(7): 778-783
40. Oberdorfer K, Wendt C (2008): MRSA - rationale und rationelle Diagnostik. Mikrobiologe 18:97-106
41. Rohde RE, Denham R, Brannon A (2009): Methicillin resistant Staphylococcusaureus: carriage ratesand characterization of students in a Texas university. Clin Lab Sci. 22(3): 176-184
42. Farley JE, Stamper PD, Ross T, Cai M, Speser S, Carroll KC (2008): Comparison of the BD GeneOhm methicillin-resistant Staphylococcusaureus (MRSA) PCR assay to culture by use of BBLCHROMagar MRSA for detection of MRSA in nasal surveillance cultures from an at-risk community population. J Clin Microbiol. 46(2): 743-746
43. Stoakes L, Reyes R, Daniel J, Lennox G, John MA, Lannigan R, et al. (2006): Prospective comparison of a new chromogenic medium, MRSASelect, to CHROMagar MRSA and mannitol-salt medium supplemented with oxacillin or cefoxitin for detection of methicillin-resistant Staphylococcusaureus. J Clin Microbiol. 44(2):637-639
44. Buhlmann M, Bogli-Stuber K, Droz S, Muhlemann K(2008):Rapid screening for carriage of methicillin-resistant Staphylococcus aureus by PCR and associated costs. J Clin Microbiol. 46(7): 2151-2154
45. van Rijen MM, Kluytmans JA (2009: Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital. Eur J Clin Microbiol Infect Dis. 28(10): 1245-1252
46. Kunori T, Cookson B, Roberts JA, Stone S, Kibbler C (2002): Costeffectiveness of different MRSA screening methods. J Hosp Infect. 51(3): 189-200
47. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM (1996): Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol. 143(5): 496-504
48. Hübner N, Hübner C, A. K (2009): Ökonomische Aspekte des Hygienemangements von MRSA. Gesundheitswesen. 71(11): 771-776
49. Dettenkofer M, Utzolino S, Luft D, Lemmen S. [Effectiveness and risks of isolation precautions in patients with MRSA and other multidrug-resistant bacteria]. Zentralbl Chir. Apr; 135(2): 124-128
50. Anonymous (2010): Stellungnahme des Vorstandes der Deutschen Gesellschaft für Krankenhaushygiene ., statt lsolierung"-Tatbestand der Körperverletzung, http//www.dgkh.de/informationen/313:DGKH2010
51. Kramer A, Hübner N-O, Steinmetz I, Ewert R, Bartels C (2009): Infektionsraten mit frühem Screening senken. Berlin Medical The Berlin Medical Journal. 06(09): 12-14
52. Hübner N-O, Kramer A, Steinmetz I, Bartels C (2009): Das Greifswalder Modell der MRSA-Prävention - Maßnahmen zur Kontrolle multiresistenter Erreger. Klinikarzt. 38:192-196
53. KramerA, HübnerN, Zygmunt M (2008): Greifswalder Präventionsstrategie greift. Deutsche Hebammen Zeitschrift. (3): 26-28